Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
about
Aripiprazole versus other atypical antipsychotics for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaQuetiapine versus placebo for schizophreniaIs the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patientsCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewGlucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Lipid profiles in schizophrenia associated with clinical traits: a five year follow-up study.Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with SchizophreniaPrevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.Behavioral interventions for antipsychotic induced appetite changes.Obesity and Serious Mental Ill Health: A Critical Review of the Literature.Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review.Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia.The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.Evolving role of mental health nurses in the physical health care of people with serious mental health illness.
P2860
Q24200904-C21A8BC3-369D-44CA-A119-368B56ECA485Q24201232-5ACFC6A7-10AC-45AE-8F22-AC3714338970Q24202305-D7979D7A-1FB6-4A91-A017-A46625AF38FEQ27027832-115D9FB0-26AD-4F87-923A-4E56AE2D386CQ28079821-E0323CF2-6F62-448F-994A-B5E2B0F23841Q34379379-15066451-C2A8-42C0-96F0-E4C626C540A7Q36063735-D410B738-345A-4E70-BE56-48976D079862Q36113742-6C7B0F05-72A7-4D7F-80DA-132C27306233Q36169130-184BEE9A-3BCA-41DC-8306-2B53151E31A0Q36621075-2ECF621C-82D8-42DB-A201-FEB4C802E28EQ36651040-59E48DE2-0265-45E5-A779-7C4588892B48Q37069133-CABA5F55-4137-4998-ABC6-BD5E6A05065DQ37354917-1AB3BB45-BD24-4358-AC7E-87685C43387DQ37516654-9D5207D3-E821-45A1-B421-EC33C1D08026Q37633458-D4B1C1E3-D914-473F-8D0D-89BDE2E893B7Q37684797-F6C2A923-B9FE-48BB-A9C8-2A74EC47381EQ37712697-1530BA08-5569-48B4-A7A5-3C68884B4A63Q38375731-E0BB8611-A657-4473-BB75-B6195923633EQ38473914-DB9D0E30-9E73-4B7E-B10D-14F5BAFFBC5DQ38599502-AE38D783-3DAB-490A-B866-63D3E1E07C9DQ38826206-44D4B33F-9C56-4E28-9EC5-860355F02B8AQ38826676-EFA29896-EA62-4BF6-8771-0BA3543532C0Q39404106-CBCDB02B-2F3E-4E9E-8ADA-5A35131A5401Q41546064-8E286EEC-762A-4221-B277-1ACFF31F9979Q42057470-336AEC34-704D-4200-8810-138A11AAD5A4Q49481418-6E14FF1C-61B1-4B61-BB9C-6D78BD174CC4Q50760224-EF59E0BE-8202-4430-B3C5-240F696F6641
P2860
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antipsychotic switching for pe ...... d weight or metabolic problems
@ast
Antipsychotic switching for pe ...... d weight or metabolic problems
@en
Antipsychotic switching for pe ...... d weight or metabolic problems
@en-gb
Antipsychotic switching for pe ...... d weight or metabolic problems
@nl
type
label
Antipsychotic switching for pe ...... d weight or metabolic problems
@ast
Antipsychotic switching for pe ...... d weight or metabolic problems
@en
Antipsychotic switching for pe ...... d weight or metabolic problems
@en-gb
Antipsychotic switching for pe ...... d weight or metabolic problems
@nl
prefLabel
Antipsychotic switching for pe ...... d weight or metabolic problems
@ast
Antipsychotic switching for pe ...... d weight or metabolic problems
@en
Antipsychotic switching for pe ...... d weight or metabolic problems
@en-gb
Antipsychotic switching for pe ...... d weight or metabolic problems
@nl
P2093
P2860
P31
P3181
P1476
Antipsychotic switching for pe ...... d weight or metabolic problems
@en
P2093
Anitha Mukundan
Guy Faulkner
P2860
P3181
P356
10.1002/14651858.CD006629.PUB2
P577
2010-12-08T00:00:00Z